Drugs / EXG102-031
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05903794 | Jul 2023 → Feb 2026 | wet macular degeneration | Exegenesis Bio | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06183814 | Oct 2023 → Dec 2025 | wet macular degeneration | Guangzhou Jiayin Biotech Ltd | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Exegenesis Bio | Regulatory Exegenesis Bio Announces FDA Clearance of Investigational New Drug (IND) Application for EXG102-031: A Novel Gene Therapy for the Treatment of neovascular Age-Related Macular Degeneration (nAMD) exegenesisbio.com ↗ |
All press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXG102-031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06183814 ↗ |
| Action | Inhibit | “EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision.” NCT06183814 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “EXG102-031 is a recombinant adeno-associated virus (rAAV) expressing an angiopoietin domain and VEGF receptor (ABD-VEGFR) fusion protein.” NCT05903794 ↗ |
| Route | Other | “EXG102-031 will be administered by subretinal injecting into one eye of each participant.” NCT05903794 ↗ |